Artelo Biosciences (ARTL) Competitors $10.80 -0.24 (-2.13%) Closing price 07/3/2025 03:49 PM EasternExtended Trading$10.80 0.00 (0.00%) As of 07/3/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. TXMD, NERV, EYEN, ALVR, ATHA, IBIO, EQ, CTXR, BGXX, and PHIOShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), iBio (IBIO), Equillium (EQ), Citius Pharmaceuticals (CTXR), Bright Green (BGXX), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors TherapeuticsMD Minerva Neurosciences Eyenovia AlloVir Athira Pharma iBio Equillium Citius Pharmaceuticals Bright Green Phio Pharmaceuticals Artelo Biosciences (NASDAQ:ARTL) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment. Does the media favor ARTL or TXMD? In the previous week, Artelo Biosciences had 12 more articles in the media than TherapeuticsMD. MarketBeat recorded 13 mentions for Artelo Biosciences and 1 mentions for TherapeuticsMD. Artelo Biosciences' average media sentiment score of 0.24 beat TherapeuticsMD's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ARTL or TXMD? Artelo Biosciences currently has a consensus price target of $33.00, suggesting a potential upside of 205.70%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of ARTL or TXMD? 0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.8% of Artelo Biosciences shares are held by company insiders. Comparatively, 2.3% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, ARTL or TXMD? TherapeuticsMD has higher revenue and earnings than Artelo Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.83M-$17.94-0.60TherapeuticsMD$1.84M7.04-$2.18MN/AN/A Is ARTL or TXMD more profitable? Artelo Biosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -114.07%. TherapeuticsMD's return on equity of -7.86% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -226.99% -164.61% TherapeuticsMD -114.07%-7.86%-5.46% Which has more risk & volatility, ARTL or TXMD? Artelo Biosciences has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. SummaryArtelo Biosciences beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.50M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.6021.5627.6620.25Price / SalesN/A283.36423.00177.43Price / CashN/A42.7336.8958.10Price / Book2.037.518.035.67Net Income-$9.83M-$55.14M$3.18B$249.21M7 Day Performance56.22%4.61%2.93%3.28%1 Month Performance60.64%0.90%1.72%3.95%1 Year Performance34.77%5.40%34.39%20.98% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.9831 of 5 stars$10.80-2.1%$33.00+205.7%+35.3%$5.50MN/A-0.605TXMDTherapeuticsMD0.8377 of 5 stars$1.11+1.8%N/A-25.8%$12.62M$1.76M0.00420Gap UpNERVMinerva Neurosciences3.1629 of 5 stars$1.77flat$5.00+182.5%-45.2%$12.38MN/A2.169News CoverageGap DownEYENEyenovia2.6256 of 5 stars$5.48+30.2%$2.00-63.5%-77.1%$12.14M$60K-0.0940Analyst UpgradeHigh Trading VolumeALVRAlloVirN/A$2.40-6.6%N/A-84.5%$12.10MN/A-0.12110Gap UpHigh Trading VolumeATHAAthira Pharma2.7377 of 5 stars$0.30-2.3%$11.25+3,700.7%-87.0%$11.83MN/A-0.1440Gap DownIBIOiBio2.1115 of 5 stars$0.71-7.6%$4.30+503.6%-61.1%$11.77M$375K0.00100High Trading VolumeEQEquillium1.8151 of 5 stars$0.29-11.3%$3.00+934.5%-51.9%$11.68M$41.10M-0.7440Gap UpCTXRCitius Pharmaceuticals2.1513 of 5 stars$1.03-4.6%$54.50+5,191.3%-83.4%$11.48MN/A0.0020High Trading VolumeBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownPHIOPhio Pharmaceuticals2.1997 of 5 stars$2.18-4.0%$14.00+542.2%-51.4%$10.87MN/A-0.2010 Related Companies and Tools Related Companies TherapeuticsMD Alternatives Minerva Neurosciences Alternatives Eyenovia Alternatives AlloVir Alternatives Athira Pharma Alternatives iBio Alternatives Equillium Alternatives Citius Pharmaceuticals Alternatives Bright Green Alternatives Phio Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
